Rankings
▼
Calendar
UTHR Q4 2016 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena
UTHR
United Therapeutics Corporation
$24B
Q4 2016 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$409M
Gross Profit
$381M
93.1% margin
Operating Income
$174M
42.6% margin
Net Income
$110M
27.0% margin
EPS (Diluted)
$2.43
QoQ Revenue Growth
+0.2%
Cash Flow
Operating Cash Flow
$163M
Free Cash Flow
$149M
Stock-Based Comp.
$105M
Balance Sheet
Total Assets
$2.3B
Total Liabilities
$463M
Stockholders' Equity
$1.9B
Cash & Equivalents
$1.0B
Revenue Segments
Remodulin
$151M
37%
Adcirca
$113M
28%
Tyvaso
$94M
23%
Orenitram
$38M
9%
Unituxin
$13M
3%
← FY 2016
All Quarters
Q1 2017 →
